Global biopharmaceutical services provider PCI Pharma Services (PCI) has expanded its biotech technologies with an investment drive of over $20 million.
PCI is significantly investing in its biotech clinical and commercial packaging at its Centre of Excellence in Philadelphia, as well as expanding cold chain capacity at numerous locations around the world.
The investment will expand PCI’s capacity for technologies for the labelling and assembly of safety syringes, auto-injector and pen devices with integrated high-speed cartoning, in-line serialisation, as well as its onsite cold chain storage.
“I am pleased to share this news regarding our continued investment to support the needs of our biotech customers,” said Salim Haffar, CEO of PCI. “It’s estimated that close to 40% of all medicines in pipeline development are biologic, and amazing new therapies are being developed and commercialised every day. With the development and commercialisation wave of biologic medicines, the market is rapidly evolving. We are proud to be the partner of choice for drug development companies as they look to outsource these specialised requirements for clinical and commercial packaging. These investments demonstrate our commitment to bring lifesaving medicines to patients around the world.”